EA033300B1 - Диоксолановые аналоги уридина для лечения рака - Google Patents

Диоксолановые аналоги уридина для лечения рака

Info

Publication number
EA033300B1
EA033300B1 EA201890648A EA201890648A EA033300B1 EA 033300 B1 EA033300 B1 EA 033300B1 EA 201890648 A EA201890648 A EA 201890648A EA 201890648 A EA201890648 A EA 201890648A EA 033300 B1 EA033300 B1 EA 033300B1
Authority
EA
Eurasian Patent Office
Prior art keywords
uridine
cancer treatment
dioxolane
analogues
dioxolane analogues
Prior art date
Application number
EA201890648A
Other languages
English (en)
Russian (ru)
Other versions
EA201890648A2 (ru
EA201890648A3 (ru
Inventor
Рикард Бетель
Андеш Энерот
Бьерн Классон
Фредрик Эберг
Original Assignee
Медивир Аб
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Медивир Аб filed Critical Медивир Аб
Publication of EA201890648A2 publication Critical patent/EA201890648A2/ru
Publication of EA201890648A3 publication Critical patent/EA201890648A3/ru
Publication of EA033300B1 publication Critical patent/EA033300B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/22—Amides of acids of phosphorus
    • C07F9/24—Esteramides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
EA201890648A 2014-08-25 2015-08-24 Диоксолановые аналоги уридина для лечения рака EA033300B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE1450983 2014-08-25
SE1550858 2015-06-22

Publications (3)

Publication Number Publication Date
EA201890648A2 EA201890648A2 (ru) 2018-08-31
EA201890648A3 EA201890648A3 (ru) 2019-02-28
EA033300B1 true EA033300B1 (ru) 2019-09-30

Family

ID=54014804

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201890648A EA033300B1 (ru) 2014-08-25 2015-08-24 Диоксолановые аналоги уридина для лечения рака
EA201790328A EA031106B1 (ru) 2014-08-25 2015-08-24 Диоксолановые аналоги уридина для лечения рака

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA201790328A EA031106B1 (ru) 2014-08-25 2015-08-24 Диоксолановые аналоги уридина для лечения рака

Country Status (24)

Country Link
US (7) US10144750B2 (cg-RX-API-DMAC10.html)
EP (2) EP3572410B1 (cg-RX-API-DMAC10.html)
JP (2) JP6663424B2 (cg-RX-API-DMAC10.html)
KR (2) KR102398714B1 (cg-RX-API-DMAC10.html)
CN (4) CN110790789B (cg-RX-API-DMAC10.html)
AU (2) AU2015308988C1 (cg-RX-API-DMAC10.html)
BR (1) BR112017003898B1 (cg-RX-API-DMAC10.html)
CA (2) CA2956251C (cg-RX-API-DMAC10.html)
CY (1) CY1122945T1 (cg-RX-API-DMAC10.html)
DK (2) DK3186244T3 (cg-RX-API-DMAC10.html)
EA (2) EA033300B1 (cg-RX-API-DMAC10.html)
ES (2) ES2927212T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20201023T1 (cg-RX-API-DMAC10.html)
HU (2) HUE059640T2 (cg-RX-API-DMAC10.html)
IL (2) IL250344B (cg-RX-API-DMAC10.html)
MX (1) MX369649B (cg-RX-API-DMAC10.html)
MY (2) MY188089A (cg-RX-API-DMAC10.html)
NZ (2) NZ729118A (cg-RX-API-DMAC10.html)
PH (2) PH12017500184A1 (cg-RX-API-DMAC10.html)
PL (2) PL3572410T3 (cg-RX-API-DMAC10.html)
PT (2) PT3186244T (cg-RX-API-DMAC10.html)
SG (3) SG10201911558UA (cg-RX-API-DMAC10.html)
WO (1) WO2016030335A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201802864B (cg-RX-API-DMAC10.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY188089A (en) * 2014-08-25 2021-11-17 Medivir Ab Prodrugs for the treatment of cancer
CN106543220A (zh) * 2015-09-16 2017-03-29 博瑞生物医药（苏州）股份有限公司 氨基磷酸酯化合物及其制备方法和晶体
PL3386998T3 (pl) 2015-12-11 2022-02-07 NuCana plc Diastereoselektywna synteza pochodnych fosforanu i proleku gemcytabiny nuc-1031
JP6968080B2 (ja) * 2016-03-02 2021-11-17 メディヴィル・アクチエボラーグ ソラフェニブ又はレゴラフェニブとトロキサシタビンのホスホロアミデートプロドラッグを用いた併用療法
CN106432328B (zh) * 2016-09-14 2019-03-22 江苏福瑞生物医药有限公司 一种索非布韦中间体的制备方法
MA46839A (fr) * 2016-11-18 2021-03-24 Neurovive Pharmaceutical Ab Promédicaments hépatiques d'ionophores de protons mitochondriaux
GB201709471D0 (en) * 2017-06-14 2017-07-26 Nucana Biomed Ltd Diastereoselective synthesis of hosphate derivatives
JP7337539B2 (ja) * 2018-06-21 2023-09-04 メディヴィル・アクチエボラーグ 白血病療法のための塩基修飾シチジンヌクレオチド
WO2019245444A1 (en) 2018-06-21 2019-12-26 Medivir Ab Base-modified cytidine nucleotides for leukemia therapy
CA3129585A1 (en) 2019-02-18 2020-08-27 Medivir Aktiebolag Methods for treating liver cancers using an orally administered dioxolane nucleotide in combination with an anti-pd1 or anti-pdl1 monoclonal antibody
CN110964057B (zh) * 2019-12-25 2022-05-06 东南大学 一种利用微流体反应装置制备索非布韦中间体的方法
CN113402546A (zh) * 2020-03-17 2021-09-17 浙江四维医药科技有限公司 一种瑞德西韦磷酸中间体尾链动态动力学拆分方法
TW202200140A (zh) * 2020-04-15 2022-01-01 瑞典商米迪維艾克提伯拉公司 用於肝癌之miv-818/樂伐替尼(lenvatinib)組合療法
CN113754692B (zh) * 2020-06-03 2022-06-10 上海交通大学 瑞德西韦中间体(s,s)-氨基磷酸酯的不对称催化合成方法
CN114685558A (zh) * 2020-12-28 2022-07-01 尚科生物医药（上海）有限公司 一种瑞德西韦中间体的制备方法
CN114249764A (zh) * 2021-11-10 2022-03-29 宁波大学 一种磷酰胺酯类前药的中间体及其制备方法与应用
WO2025155547A1 (en) * 2024-01-17 2025-07-24 University Of Georgia Research Foundation, Inc. An efficient synthesis of beta-l-5-[(e)-2-bromovinyl)-1-((2s,4s)-2-(hydroxymethyl)-1,3-(dioxolane-4-yl) uracil)] (l-bhdu) via chiral pure l-dioxolane

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2157215C2 (ru) * 1992-10-28 2000-10-10 Эмори Юниверсити Способ лечения инфекций, вызываемых вирусом гепатита в
WO2002030922A2 (en) * 2000-10-13 2002-04-18 Shire Biochem Inc. Dioxolane analogs for improved inter-cellular delivery
WO2005012327A2 (en) * 2003-07-21 2005-02-10 University College Cardiff Consultants Limited Nucleotide phosphoramidates as anticancer agents
WO2016030335A1 (en) * 2014-08-25 2016-03-03 Medivir Ab Dioxolane analogues of uridine for the treatment of cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6022876A (en) * 1996-11-15 2000-02-08 Yale University L-β-dioxolane uridine analogs and methods for treating and preventing Epstein-Barr virus infections
WO2007106450A2 (en) * 2006-03-10 2007-09-20 University Of Georgia Research Foundation, Inc. Diketo acids with nucleobase scaffolds: anti-hiv replication inhibitors targeted at hiv integrase in combination therapy
CN101534835B (zh) * 2006-09-01 2012-05-30 佐治亚大学研究基金会 用于癌症的L-OddC的前药
PL216525B1 (pl) * 2006-10-17 2014-04-30 Ct Badań Molekularnych I Makromolekularnych Polskiej Akademii Nauk 5'-O-[(N-acylo)amidoditiofosforano] nukleozydy oraz sposób wytwarzania 5'-O-[(N-acylo)amidofosforano]-,5'-O-[(N-acylo)amidotiofosforano]-, 5'-O-[(N-acylo)amidoditiofosforano]nukleozydów
US20130143835A1 (en) * 2011-12-05 2013-06-06 Medivir Ab HCV Polymerase Inhibitors
EP3074411A2 (en) 2013-11-27 2016-10-05 Idenix Pharmaceuticals LLC Nucleotides for the treatment of liver cancer

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2157215C2 (ru) * 1992-10-28 2000-10-10 Эмори Юниверсити Способ лечения инфекций, вызываемых вирусом гепатита в
WO2002030922A2 (en) * 2000-10-13 2002-04-18 Shire Biochem Inc. Dioxolane analogs for improved inter-cellular delivery
WO2005012327A2 (en) * 2003-07-21 2005-02-10 University College Cardiff Consultants Limited Nucleotide phosphoramidates as anticancer agents
WO2016030335A1 (en) * 2014-08-25 2016-03-03 Medivir Ab Dioxolane analogues of uridine for the treatment of cancer

Also Published As

Publication number Publication date
HRP20201023T1 (hr) 2020-10-16
MX369649B (es) 2019-11-15
CN111269264A (zh) 2020-06-12
US11447511B2 (en) 2022-09-20
EP3186244A1 (en) 2017-07-05
US10822360B2 (en) 2020-11-03
IL250344A0 (en) 2017-03-30
US10336780B2 (en) 2019-07-02
SG10202001117YA (en) 2020-04-29
SG11201701172SA (en) 2017-03-30
EA201890648A2 (ru) 2018-08-31
US20230382931A1 (en) 2023-11-30
KR102398714B1 (ko) 2022-05-17
ZA201802864B (en) 2019-07-31
EA201790328A1 (ru) 2017-08-31
MY188089A (en) 2021-11-17
NZ729118A (en) 2022-02-25
PL3186244T3 (pl) 2020-11-16
EP3572410A1 (en) 2019-11-27
AU2018201980B2 (en) 2019-05-16
PH12017500184B1 (en) 2017-06-28
CY1122945T1 (el) 2021-10-29
CN107074826A (zh) 2017-08-18
CN110804072A (zh) 2020-02-18
US20230117570A1 (en) 2023-04-20
CA2956251A1 (en) 2016-03-03
JP6663424B2 (ja) 2020-03-11
JP2020090535A (ja) 2020-06-11
EA201890648A3 (ru) 2019-02-28
NZ762628A (en) 2023-04-28
EA031106B1 (ru) 2018-11-30
US10654877B2 (en) 2020-05-19
PT3572410T (pt) 2022-09-15
CN110790789B (zh) 2023-05-12
US20170267705A1 (en) 2017-09-21
HUE059640T2 (hu) 2022-12-28
DK3572410T3 (da) 2022-08-29
CA3128645A1 (en) 2016-03-03
EP3186244B1 (en) 2020-04-22
WO2016030335A1 (en) 2016-03-03
AU2015308988C1 (en) 2018-09-06
CN107074826B (zh) 2020-05-22
MY198325A (en) 2023-08-24
JP2017526677A (ja) 2017-09-14
ES2927212T3 (es) 2022-11-03
DK3186244T3 (da) 2020-07-13
PL3572410T3 (pl) 2022-10-03
ES2796089T3 (es) 2020-11-25
AU2015308988A1 (en) 2017-02-23
BR112017003898B1 (pt) 2022-10-18
KR102396905B1 (ko) 2022-05-13
KR20170046736A (ko) 2017-05-02
US20200239502A1 (en) 2020-07-30
CA3128645C (en) 2023-06-27
SG10201911558UA (en) 2020-01-30
HUE050705T2 (hu) 2020-12-28
US10144750B2 (en) 2018-12-04
IL266766B (en) 2020-05-31
IL266766A (en) 2019-07-31
PT3186244T (pt) 2020-05-29
US20210054008A1 (en) 2021-02-25
AU2018201980A1 (en) 2018-04-12
AU2015308988B2 (en) 2018-04-26
BR112017003898A2 (pt) 2017-12-05
US20190100541A1 (en) 2019-04-04
EP3572410B1 (en) 2022-07-20
PH12019501919A1 (en) 2020-09-14
KR20200035482A (ko) 2020-04-03
CA2956251C (en) 2022-10-25
IL250344B (en) 2020-01-30
JP6905609B2 (ja) 2021-07-21
US20190389890A1 (en) 2019-12-26
CN110790789A (zh) 2020-02-14
CN110804072B (zh) 2023-05-12
MX2017002328A (es) 2017-05-22
PH12017500184A1 (en) 2017-06-28

Similar Documents

Publication Publication Date Title
EA033300B1 (ru) Диоксолановые аналоги уридина для лечения рака
MX2022009148A (es) Composiciones y metodos para el tratamiento de hemoglobinopatias.
MX394380B (es) Compuestos dinucleótidos cíclicos para eltratamiento de cáncer
EA201991862A1 (ru) Композиции и способы, предназначенные для лечения гемоглобинопатий
EA201990221A1 (ru) 1,3-дигидроксифенильные производные, применимые в качестве иммуномодуляторов
EA201990296A1 (ru) Антитела против siglec-7 для лечения рака
ZA202001717B (en) Compounds, salts thereof and methods for treatment of diseases
EA201892147A1 (ru) Бициклические соединения
EA201891910A1 (ru) Гетероарильные ингибиторы pad4
EA201890373A1 (ru) Пиридиновые соединения, пригодные для борьбы с фитопатогенными грибами
EA201892229A1 (ru) Замещенные аминопуриновые соединения, содержащие их композиции и способы лечения с их применением
EA201891200A1 (ru) Композиции, содержащие бактериальные штаммы
MX2018009325A (es) Compuestos y metodos para tratar enfermedades mediadas por el acido ribonucleico (arn).
EA201691857A1 (ru) Соединения, применимые в качестве иммуномодуляторов
EA201692526A1 (ru) Замещенные [1,2,4]триазольные соединения
EA201891251A1 (ru) Бициклические ингибиторы pad4
EA201691913A1 (ru) Замещенные [1,2,4]триазольные и имидазольные соединения в качестве фунгицидов
EA201890858A1 (ru) 2,4-дигидроксиникотинамиды как агонисты apj
EA201990400A1 (ru) Соединения и композиции и их применение
EA201891347A1 (ru) Аза-бензимидазольные ингибиторы pad4
EA201991580A1 (ru) Пиримидиновое соединение и его фармацевтическое применение
EA201692525A1 (ru) Замещенные соединения [1,2,4]триазола и имидазола в качестве фунгицидов
EA201792287A1 (ru) Способы лечения рака
EA201691412A1 (ru) Гидроксиформамидные производные и их применение
EA201792096A2 (ru) РАППγ АГОНИСТЫ ДЛЯ ЛЕЧЕНИЯ РАССЕЯННОГО СКЛЕРОЗА

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM